The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.

Bibliographic Details
Uniform Title:American psychiatric association practice guidelines (series)
Corporate Author: American Psychiatric Association (Author, Issuing body)
Language:English
Published: Arlington, VA : American Psychiatric Association, [2016]
Edition:First edition.
Series:American psychiatric association practice guidelines (series)
Subjects:
Dementia > Chemotherapy.
Antipsychotic drugs.
Dementia > drug therapy.
Dementia > complications.
Antipsychotic Agents > therapeutic use.
Psychomotor Agitation > drug therapy.
Psychotic Disorders > drug therapy.
Practice Guideline.
Genre:
Practice Guideline.
Physical Description:vii, 210 pages : illustrations ; 28 cm.
Variant Title:
Practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia
Format: Book
Contents:
  • Machine generated contents note: Overview of the Development Process
  • Rating the Strength of Research Evidence and Recommendations
  • Proper Use of Guidelines
  • Guidelines and Implementation
  • Guideline Statements
  • Assessment of Behavioral/Psychological Symptoms of Dementia
  • Development of a Comprehensive Treatment Plan
  • Assessment of Benefits and Risks of Antipsychotic Treatment for the Patient
  • Dosing, Duration, and Monitoring of Antipsychotic Treatment
  • Use of Specific Antipsychotic Medications, Depending on Clinical Context
  • Rationale
  • Potential Benefits and Harms
  • Benefits
  • Harms
  • Costs
  • Balancing of Benefits and Harms in Rating the Strength of Recommendations
  • Limitations of the Evidence in Assessing Benefits and Harms
  • Implementation
  • Assessment of Behavioral/Psychological Symptoms of Dementia
  • Development of a Comprehensive Treatment Plan
  • Assessment of Benefits and Risks of Antipsychotic Treatment for the Patient
  • Dosing, Duration, and Monitoring of Antipsychotic Treatment
  • Use of Specific Antipsychotic Medications, Depending on Clinical Context
  • Quality Measurement Considerations
  • Existing Measures of Relevance to Antipsychotic Use in Individuals With Dementia
  • Variability in Practice That May Be Addressed by Quality Measures
  • Potential Options for Measure Development
  • Practical Barriers to Measure Development
  • Additional Uses of Guideline Recommendations to Enhance Quality
  • Guideline Development Process
  • Management of Potential Conflicts of Interest
  • Guideline Writing Group Composition
  • Expert Opinion Data Collection
  • Systematic Review Methodology
  • Rating the Strength of Supporting Research Evidence
  • Rating the Strength of Recommendations
  • External Review
  • Approval
  • Glossary of Terms
  • References
  • Disclosures
  • Individuals and Organizations That Submitted Comments
  • Appendix A Review of Available Evidence
  • Clinical Questions
  • Review of Supporting Research Evidence
  • 1A. Efficacy and Comparative Effectiveness of Second-Generation Antipsychotics for Overall BPSD
  • 1B. Efficacy and Comparative Effectiveness of Second-Generation Antipsychotics for Treatment of Agitation
  • 1C. Efficacy and Comparative Effectiveness of Second-Generation Antipsychotics for Treatment of Psychosis
  • 2. Appropriate Dosage and Duration of Antipsychotic Treatment in Individuals With Alzheimer's Disease and Other Dementia Syndromes
  • 3. Effects of Specific Patient Characteristics on Effectiveness and Harms of Antipsychotic Medications in Individuals With Dementia
  • 4. Potential Adverse Effects and/or Complications Involved With Prescribing Second-Generation Antipsychotics to Patients
  • Appendix B Expert Opinion Survey Data: Results
  • Section I Questions About Appropriate Use
  • Section II Duration of Treatment.